About Tvardi Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://tvarditherapeutics.com
Frequently Asked Questions
What is the 52-week range for TVRD?
The 52-week high is $43.65 and the 52-week low is $0.93.
What is the P/E ratio for TVRD?
The P/E ratio data is currently unavailable.
What is the dividend yield for TVRD?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -145.40%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -700.06%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.93.
Analyst Recommendation Trends
Wall Street analyst consensus for TVRD over the last few months:
Latest TVRD News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV) shares moved
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA) shares rose
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen (NASDAQ:SRZN) stock
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven disease biology Collective findings now span multiple preclinical models of UC, further supporting the scientific rationale for advancing TTI-109, Tvardi’s next-generation STAT3 inhibitor, in UC HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or t
Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciences
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-09 | Shiff Susan Ph.D. | +6,000 | - | - |
| 2026-06-09 | HALL WALLACE L JR | +6,000 | - | - |
| 2026-06-09 | Smith Cynthia | +6,000 | - | - |
| 2026-06-09 | Shah Sujal | +6,000 | - | - |
| 2026-06-09 | WYZGA MICHAEL S | +6,000 | - | - |
| 2026-01-29 | Conn Avi Daniel | +45,000 | - | - |
| 2026-01-29 | O'Brien Stephen Paul | +15,000 | - | - |
| 2026-01-29 | Alibhai Imran Nizamudin | +115,000 | - | - |
| 2026-01-29 | Kauh John Saewook M.D. | +45,000 | - | - |
| 2025-12-16 | Conn Avi Daniel | +17,500 | - | - |
| 2025-12-16 | O'Brien Stephen Paul | +4,000 | - | - |
| 2025-12-16 | Alibhai Imran Nizamudin | +47,500 | - | - |
| 2025-12-16 | Kauh John Saewook M.D. | +17,500 | - | - |